Total Payments
$3,402
2024 Payments
$472.43
Companies
7
Transactions
15
Payment Breakdown by Category
Research$3,054 (89.8%)
Food & Beverage$257.37 (7.6%)
Education$91.00 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,054 | 7 | 89.8% |
| Food and Beverage | $257.37 | 6 | 7.6% |
| Education | $91.00 | 2 | 2.7% |
Payments by Type
Research
$3,054
7 transactions
General
$348.37
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $3,191 | 8 | $0 (2024) |
| Esperion Therapeutics, Inc. | $91.00 | 2 | $0 (2021) |
| Abbott Laboratories | $47.90 | 1 | $0 (2022) |
| Preventice Services, LLC | $19.67 | 1 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $18.84 | 1 | $0 (2019) |
| Philips Electronics North America Corporation | $18.52 | 1 | $0 (2022) |
| BOSTON SCIENTIFIC CORPORATION | $14.97 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $472.43 | 2 | Regeneron Pharmaceuticals, Inc. ($472.43) |
| 2023 | $2,719 | 6 | Regeneron Pharmaceuticals, Inc. ($2,719) |
| 2022 | $66.42 | 2 | Abbott Laboratories ($47.90) |
| 2021 | $91.00 | 2 | Esperion Therapeutics, Inc. ($91.00) |
| 2019 | $38.51 | 2 | Preventice Services, LLC ($19.67) |
| 2018 | $14.97 | 1 | BOSTON SCIENTIFIC CORPORATION ($14.97) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $327.37 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 03/05/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $145.06 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/12/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $137.47 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/11/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $467.19 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/20/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $1,504.31 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/15/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $128.25 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/13/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $370.17 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 02/02/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $111.52 | Research |
| Study: A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/03/2022 | Philips Electronics North America Corporation | (5044) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $18.52 | General |
| Category: Medical Device | ||||||
| 10/25/2022 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $47.90 | General |
| Category: Heart Failure | ||||||
| 01/26/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Education | In-kind items and services | $51.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 01/26/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Education | In-kind items and services | $40.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/04/2019 | Preventice Services, LLC | — | Food and Beverage | Cash or cash equivalent | $19.67 | General |
| Category: Cardiovascular Monitors | ||||||
| 03/29/2019 | Alexion Pharmaceuticals, Inc. | Kanuma (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Immunology | ||||||
| 01/22/2018 | BOSTON SCIENTIFIC CORPORATION | GENERAL PAIN MANAGEMENT (Device) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: PAIN MANAGEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A THREE-PART, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EVINACUMAB IN PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $3,054 | 7 |
About Dr. Carissa Baker-Smith, M.D
Dr. Carissa Baker-Smith, M.D is a Pediatrics healthcare provider based in Wilmington, Delaware. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508031121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carissa Baker-Smith, M.D has received a total of $3,402 in payments from pharmaceutical and medical device companies, with $472.43 received in 2024. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "" ($3,054).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Cardiology, Pediatric Cardiology
- Location Wilmington, DE
- Active Since 04/24/2008
- Last Updated 02/06/2020
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1508031121
Products in Payments
- EVKEEZA (Biological) $3,191
- NEXLETOL (Drug) $91.00
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $47.90
- Kanuma (Drug) $18.84
- (5044) MCOT (Device) $18.52
- GENERAL PAIN MANAGEMENT (Device) $14.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Wilmington
Harry Chugani, Md, MD
Pediatrics — Payments: $73,932
Pediatrics $73,932
E Kolb, Md, MD
Pediatrics — Payments: $54,692
Pediatrics $54,692
Dr. Kateryna Kotlyarevska, Md, MD
Pediatrics — Payments: $35,871
Pediatrics $35,871
Dr. Deborah Consolini, Md, MD
Pediatrics — Payments: $35,032
Pediatrics $35,032
Dr. J. Malatack, M.d, M.D
Pediatrics — Payments: $25,720
Pediatrics $25,720
Michael Cellucci, Md, MD
Pediatrics — Payments: $21,544
Pediatrics $21,544